Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05880524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)

Study acronym: ReSCInD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv7 Show 5 more changesShow less
    • Primary completion date: Dec 2025 to Mar 2028
    • Start date: Dec 2024 to Oct 1, 2026
    • Study sites: 1 to 5
    • Study completion date: Jan 2026 to Jul 2028
    • Collaborators revised (2)
  2. Primary completion date: Dec 2024 to Dec 2025v6 Show 4 more changesShow less
    • Start date: Dec 2023 to Dec 2024
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Jan 2025 to Jan 2026
    • Site details revised
  3. Start date: Oct 2023 to Dec 2023v5
  4. Start date: Jul 2023 to Oct 2023v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2023 to Jul 2023
    • Site details revised
    v3
  6. Start date: May 2023 to Jun 2023
    • Collaborators: 4 to 2
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this (multicentric, randomised, placebo-controlled single-blinded; phase 2) clinical trial is to test the hypothesis that DNase 1 administration leads to a reduction in systemic immune response measured in patients after acute ischaemic stroke compared to control treatment. Participants will receive intravenous DNase 1 (500 µg/kg) or placebo (NaCl 0.9%) twice within 24±6 hours after symptom onset (last seen well). Blood samples will be taken at baseline, day 1 and 3. Personal visits will occur on baseline, day 1, 3 and discharge date. A telephone interview will be conducted on day 30±3.
Trial Details
NCT Number NCT05880524
Lead Sponsor Ludwig-Maximilians - University of Munich
Collaborators: University Hospital Erlangen, Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)		 Ischemic Stroke, Inflammatory Response
Related terms Ischemic Stroke
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov